These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17146873)
21. The molecular staging of prostate cancer. Yardy G; McGregor S; Bodmer W BJU Int; 2005 Apr; 95(6):907. PubMed ID: 15794810 [No Abstract] [Full Text] [Related]
22. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Roach M; Weinberg V; Sandler H; Thompson I Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758 [TBL] [Abstract][Full Text] [Related]
23. Radial distance of extraprostatic extension measured by an ocular micrometer is an independent predictor of prostate-specific antigen recurrence: a new proposal for the substaging of pT3a prostate cancer. Epstein JI Am J Surg Pathol; 2008 Feb; 32(2):337-8; author reply 338-40. PubMed ID: 18223339 [No Abstract] [Full Text] [Related]
24. Management of early prostate cancer. Stewart A Eur J Cancer Care (Engl); 2007 Nov; 16(6):461. PubMed ID: 17944759 [No Abstract] [Full Text] [Related]
25. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649 [TBL] [Abstract][Full Text] [Related]
26. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [TBL] [Abstract][Full Text] [Related]
27. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. Tonita JM; Skarsgard D; Muhajarine N Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504 [TBL] [Abstract][Full Text] [Related]
28. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547. Atmaca AF; Balbay MD J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084 [No Abstract] [Full Text] [Related]
29. Sweet's syndrome in prostate cancer. Glendenning J; Khoo V Prostate Cancer Prostatic Dis; 2008; 11(4):397-8. PubMed ID: 18227857 [TBL] [Abstract][Full Text] [Related]
30. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. D'Amico AV; Chen MH J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151 [No Abstract] [Full Text] [Related]
31. Localized prostate cancer: can we better define who is at risk of unfavourable outcome? Joniau S; Van Poppel H BJU Int; 2008 Mar; 101 Suppl 2():5-10. PubMed ID: 18307686 [TBL] [Abstract][Full Text] [Related]
32. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695 [TBL] [Abstract][Full Text] [Related]
33. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Mucci LA; Pawitan Y; Demichelis F; Fall K; Stark JR; Adami HO; Andersson SO; Andrén O; Eisenstein AS; Holmberg L; Huang W; Kantoff PW; Perner S; Stampfer MJ; Johansson JE; Rubin MA Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):249-51. PubMed ID: 18199732 [TBL] [Abstract][Full Text] [Related]
34. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy. Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491 [TBL] [Abstract][Full Text] [Related]
36. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. Okamoto H; Terai C; Kamatani N BJU Int; 2004 Dec; 94(9):1401-2. PubMed ID: 15610133 [No Abstract] [Full Text] [Related]
37. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related]
38. Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma. Puppo P Eur Urol; 2007 Sep; 52(3):639-41. PubMed ID: 17451871 [No Abstract] [Full Text] [Related]
39. [Clinical study of stage a prostatic cancer detected incidentally by transurethral resection of the prostate]. Nakanishi S; Gotou T; Sawada A; Shibasaki N; Ishitoya T; Okumura K Hinyokika Kiyo; 2009 Jan; 55(1):5-8. PubMed ID: 19227204 [TBL] [Abstract][Full Text] [Related]